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Although population exposure to lead has declined, chronic lead toxicity remains a major public
health problem in the United States affecting millions of children and adults. Important gaps exist
in knowledge of the pathophysiology of chronic lead intoxication. These gaps have impeded
development of control strategies. To close current gaps in knowledge of chronic lead toxicity,
we propose an integrated, multidisciplinary, marker-based research program. This program
combines a) direct measurement of individual lead burden by 109Cd X-ray fluorescence analysis of
lead in bone, b) determination of ALA-D phenotype, an index of individual susceptibility to lead,
and c) assessments of subclinical injury produced by lead in the kidneys, nervous system and,
reproductive organs. Data from this research will provide answers to questions of great public
health importance: a) Are current environmental and occupational standards adequate to prevent
chronic lead intoxication? b) Is lead mobilized from the skeleton during pregnancy or lactation to
cause fetal toxicity? c) Is lead mobilized from bone during menopause to cause neurotoxicity?
d) What is the significance of genetic variation in determining susceptibility to lead? e) What is
the contribution of lead to hypertension, renal disease, chronic neurodegenerative disease or
declining sperm counts? f) Is chelation therapy effective in reducing body lead burden in persons
with chronic overexposure to lead? Environ Health Perspect 104(Suppl 1):141-146 (1996)
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Introduction
Chronic lead toxicity is a major public
health problem in the United States (1-3).
Although population blood lead levels have
declined (4), chronic lower level exposure
to lead remains widespread. Approximately
2 million preschool children are estimated
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to have blood lead levels above the federal
guideline of 10 pig/dl, and 200,000 have
levels above 25 pg/dl (2). More than 1.4
million adult workers have potential occu-
pational lead exposure (5), and thousands
have documented elevations in blood lead
levels (6-9).
Lead is understood today to cause
adverse effects at levels of exposure that
produce no clinically detectable symptoms
and that only a few years ago were thought
to be safe (1). This recognition of sub-
clinical toxicity first arose from studies in
young children showing that chronic
asymptomatic exposure to lead could cause
irreversible injury to the nervous system
(10-14). The underlying premise is that
there exists a dose-related continuum of
toxicity, in which the clinically apparent
effects oflead, many ofwhich have been
known for millennia (15), have their
asymptomatic subclinical analogs (16).
What Are the Gaps
in Knowledge of
Chronic Lead Toxicity?
Serious gaps exist in knowledge of the
chronic, subclinical toxicity of lead and
dose-response relationships are still largely
uncertain. Little information is available on
whether there exist threshold levels below
which no toxic effects can be detected. The
contribution ofstored lead to lead toxicity
remains primarily the subject of case report
and conjecture. Specific gaps in knowledge
include the following (17-21):
* What is the threat to human health of
lead stored in bone? Under what cir-
cumstances is this lead released, and
how much is released?
* Is lead mobilized from bone during
pregnancy a threat to mother or baby?
Can it cause fetal neurotoxicity in
utero? Should certain high-risk women
be evaluated for body lead burden prior
to becoming pregnant? If their levels
are high, should they be chelated? Is
chelation effective in reducing body
lead burdens in women with chronic
overexposure? Is such lead a legacy of
environmental injustice?
* Is lead mobilized from bone during
menopause to cause adverse effects on
the health of women, including neu-
ropsychological dysfunction? How can
this mobilization be prevented?
* What is the relationship between male
reproductive impairment and chronic
exposure to lead? Male reproductive
impairment with reduction of sperm
count has been observed in men heavily
exposed to lead but has not been sys-
tematically studied in men with more
modest exposures using more recently
developed technologies for assessing
reproductive dysfunction (19,20). It is
not known whether the male reproduc-
tive impairment caused by lead is due
to direct testicular toxicity or is medi-
ated through neuroendocrine disrup-
tion (16). Also it is not known whether
lead has played a role in the decline in
sperm counts observed among men in
industrialized nations.
* What is the contribution of lead to
chronic neuropsychological dysfunction
in adults (18)? What is the possible
contribution of lead to chronic neuro-
logical degenerative diseases, such as
dementias and movement disorders?
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* What is the relationship between lead
dose (both acute and chronic) and renal
dysfunction? Does a threshold exist for
this damage? What is the earliest dam-
age that occurs, and at what level of
exposure does it occur? Are currently
available biological markers adequate
for tracing such damage (17)?
* What is the relationship between lead
and hypertension? Is there a threshold?
Is it a renal or a vascular phenomenon,
and are there differences in susceptibil-
ity between racial groups? Does lead,
perhaps lead mobilized from skeletal
stores, constitute a potentially pre-
ventable cause of pregnancy-induced
hypertension? What is the contribution
of lead to patterns ofhypertension in
the United States?
* What is the significance to lead toxicity
of genetically determined polymor-
phism in enzymes susceptible to inhibi-
tion by lead (21)?
* Are current occupational and environ-
mental standards sufficiently stringent
to protect against lead toxicity?
What Obstacles
Have Impeded Research
on Chronic Lead Toxicity?
The fundamental impediment to the study
ofchronic lead toxicityhas been alack, until
relatively recendy, ofwell-validated biologic
markers (22), specifically a) the absence of
a reliable biologic indicator of cumulative
lead dose or body lead burden; b) the
absence ofbiologic markers of individual
genetic susceptibility; and c) the availabil-
ity ofonly a limited array ofwell-validated
biologic markers ofsubclinical toxicity.
A Research Strategy
to Understand the
Chronic Toxicity of Lead
The central thesis ofthis review is that crit-
ical public health questions concerning the
chronic toxicity oflead can be answered
and the above obstacles overcome, through
systematic application in clinical and
epidemiologic studies of an integrated,
marker-based strategy. We argue that sup-
port for such a strategy continue to be a
high priority for research in environmental
health in the United States because of the
continuing wide extent of the problem of
lead toxicity. The principal elements ofthe
strategy are
Assessment ofcumulative lead absorp-
tion and lead mobilization through
measurement of body lead burden
using 109Cd-based K shell X-ray
fluorescence (KXRF) analysis oflead in
bone (23);
* Evaluation of the molecular genetic
basis ofindividual variation in suscepti-
bility to lead through examination of
genetic polymorphism in the enzyme
8-aminolevulinic acid dehydratase
(ALAD) (21).
* Detection ofsubclinical toxic effects on
kidney function and hypertension
through application of biochemical
indices of renal function and vascular
reactivity (17);
* Assessment ofsubclinical toxic effects
on the central and peripheral nervous
system by application ofvalidated test
instruments, including computerized
and manual assessment batteries, stan-
dardized nerve conduction velocity
measurements, measurements of
evoked potentials, assessment of pos-
tural stability, and assessments ofauto-
nomic function.
* Assessment of reproductive effects by
application ofnewly developed parame-
ters for assessing sperm function and
endocrine status.
The strength of this strategy is in its
simultaneous use of three classes of bio-
logic markers: exposure, toxic outcome,
and susceptibility (22).
Measurementofthe
BodyBurden ofLead
The cornerstone of the strategy proposed
here is the direct, noninvasive measure-
ment of the body lead burden through
measurement oflead in bone (23).
The lead body burden represents the
difference between cumulative lifetime
absorption of lead from all sources and
total excretion (24). Lead is not distrib-
uted homogeneously in the human body.
Experimental studies have shown instead
that it is dispersed among several physio-
logically distinct compartments that differ
from one another in size and accessibility
(25). These compartments and their inter-
relations can be portrayed by metabolic
models that describe the absorption, distri-
bution, deposition, accumulation, and
excretion of lead both qualitatively and
quantitatively. Such models have been pro-
posed by several authors, for example, by
Marcus et al. (26-28), O'Flaherty (29),
and Leggett (30). A reasonable portrayal of
the functional anatomy of the body lead
burden is provided by the model of
Rabinowitz and coworkers (31). This
model is based on stable isotope and meta-
bolic balance studies. It proposes that the
lead burden be described in terms ofthree
dynamically interrelated compartments.
Lead in Blood. Lead in blood com-
prises about 1% ofthe body lead burden in
the Rabinowitz model (31). Because it is
conveniently accessible and is the fraction
of the body burden that correlates most
closely with recent environmental expo-
sures, it is the component measured most
frequently. A large percentage of the lead
in blood is found in the erythrocytes. The
half-life oflead in blood is 36 ± 5 days.
Soft Tissue Lead. Compartment 2 in
the Rabinowitz model is composed princi-
pally of soft tissue lead (31). The contact
between lead and soft tissues such as the
kidneys and nervous system is responsible
for most oflead's toxicity.
Skeletal Lead. Lead in the skeleton is
the largest component ofthe body burden
(24). This compartment contains about
95% of all lead in the human body in
adults, and approximately 70% in children.
Quantitative estimates of the biological
half-life oflead in bone vary. Data suggest
that the half-life may depends on bone
type (i.e., cortical or trabecular) or even
bone-site; the turnover oflead in trabecular
bone appears to be substantially more rapid
than that in cortical bone. Most estimates
give a half-life oflead in bone that is mea-
sured in years or even decades. It should be
noted that these estimates have shown a
tendency to increase as new data from
ongoing longitudinal studies ofretired lead
workers have become available.
Direct analysis oflead in the skeleton
by XRF overcomes a major limitation that
plagued previous research on chronic lead
toxicity, namely, the lack ofa sensitive and
specific biologic marker ofcumulative lead
exposure (23).
Three methods have been developed to
measure lead in bone in vivo (32). The
method using 109Cd-based fluorescence of
the K shell X-rays oflead has been applied
most widely because of its intrinsic
methodological advantages, including a
high degree of measurement accuracy
that is robust against movement by the
subject and independent ofoverlying tissue
thickness (33-37).
Bone lead measurements complement,
but do not replace, blood and plasma lead
determinations. Most epidemiologic stud-
ies of populations chronically exposed to
lead use bone and blood lead measure-
ments in combination to assess past plus
current exposure.
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6-Aminolevulinic Acid
Dehydratase: A Marker
of Susceptibility to Lead
Substantial interest surrounds the hypothe-
sis that there exists a genetic basis for
observed interindividual differences in sus-
ceptibility to lead (21). The hypothesis
that genetic polymorphism in the home
biosynthetic enzyme ALAD accounts, at
least in part, for this variability has been
generated by researchers at the Mount
Sinai Medical Center (38).
Human ALAD has been shown by
Petrucci and coworkers (39) to be a poly-
morphic enzyme with two common alleles,
ALAD' and ALAD2. This results in an
enzyme system with three distinct isozyme
phenotypes, designated AIAD 1-1, ALAD
1-2 and ALAD 2-2. These isozymes sepa-
rate by starch gel electrophoresis. In an
Italian population, the frequencies of the
phenotypes were 1-1 (81%), 1-2 (17%)
and 2-2 (2%), consistent with gene fre-
quencies of0.90 and 0.10 for the ALAD'
and ALAD2 alleles, respectively. Similar
results were obtained in other European
populations, whereas existence of the
ALAD2 allele was not observed in a large
sample ofAfricans from Liberia (40).
The existence of this common poly-
morphism, coupled with the fact that
ALAD is markedly inhibited by lead, sug-
gests that there could be a physiologic rela-
tionship between the frequency of the
ALAD2 allele and lead poisoning. It was
hypothesized that individuals with the
ALAD2 allele would be more susceptible to
the detrimental effects oflead exposure if
the ALAD2 subunit bound lead more
tightly than theALAD1 subunit (38).
To test this hypothesis, ALAD isozyme
types were determined at the Mount Sinai
Medical Center in 1277 blood samples
obtained from the New York City blood
lead screening program (38). The blood
lead level and ALAD isozyme determina-
tions were performed in double-blind fash-
ion. The major finding was that the
population homozygous or heterozygous
for ALAD2 had significantly higher mean
blood lead levels than those homozygous
for ALAD'. These data support the hypo-
thesis of a relation between the ALAD2
allele and the accumulation of lead in
blood. Similar data in other populations
support an identical conclusion (41,42).
Determination ofALAD genotype can
be accomplished accurately and inexpen-
sively using a PCR method developed by
Wetmur et al. (43). Population studies
incorporating the ALAD biomarker have
found significant correlations between
ALAD phenotype, blood lead levels, and
bone lead levels (44).
In the future, to understand further the
chronic toxicity of lead, additional inte-
grated marker-based studies will be needed
that combine determination of ALAD
phenotype with measures of lead body
burden and subclinical toxic outcomes.
Anemia, including anemia due to G6PD
deficiency (45), has long been known to
increase susceptibility to lead intoxication.
Although the ALAD studies have been
controlled for anemia, simultaneous analy-
sis ofALAD and G6PD polymorphisms
might be informative. In addition, studies
should be undertaken to identify other
polymorphic markers for increased lead
susceptibility, such as the newly described
erythrocyte metallothionein lead-binding
protein (46).
Biochemical and Physiologic
Markers to Assess
Subclinical Lead Toxicity
RenalToxicity
Chronic nephropathy, which may progress
to kidney failure, is the classic manifesta-
tion of lead toxicity in the kidneys
(17,47,48). It appears to result from long-
term, relatively high-dose exposure to lead,
but dose-response relationships have not
been well defined.
The evolution of lead nephropathy is
usually silent. The central event appears to
be the progressive destruction of tubular
cells by lead and their replacement with
fibrosis (17). Clinical manifestations of
impairment, such as elevations in blood
urea nitrogen (BUN) or serum creatinine,
do not ordinarily become evident until
50 to 75% of the nephrons have been
destroyed (49).
The most important research need in
the study oflead nephropathy is a reliable
early biologic indicator ofthe kidney dam-
age induced by lead (49). Such a marker
would permit better assessment of dose-
response relationships in epidemiologic
studies and might permit early identifi-
cation ofand intervention against evolving
lead nephropathy (50).
Promising biomarkers oflead nephro-
toxicity include the following assays of
glomerular and tubular function:
Glomerular Function. Isolated urinary
excretion ofhigh-molecular weight pro-
teins, such as albumin, appears to be
a reliable biologic marker ofearly glo-
merular dysfunction (51). Measurement
of creatinine clearance remains, how-
ever, the "gold standard" for noninva-
sive assessment ofglomerular function.
Despite its relative difficulty of accom-
plishment, careful consideration should
be given to its inclusion in longitudinal
epidemiologic studies of progressive
renal dysfunction in populations
exposed to lead.
Tubular Function. Lead-induced dys-
function ofthe proximal renal tubules
is best assessed by measuring urinary
excretion ofa battery oflow-molecular
weight proteins (52). Suggested candi-
dates include: N-acetyl-p-glucosamini-
dase (NAG), y-glutamyltransferase
(GGT), lactate dehydrogenase (LDH),
,B-2-microglobulin (P-2MG), and
retinol binding protein (RBP).
A recent epidemiologic study ofa popu-
lation with occupational exposure to lead
suggests that increased excretion of NAG
may be especially sensitive to recent increases
in the body lead burden, though not so
much as to cumulative lead dose (53).
Additional prospective epidemiologic
studies are needed that combine molecular
markers of nephrotoxicity with markers
oflead body burden and ALAD genotype.
Only through longitudinal follow-up
of exposed populations through such
studies will the evolution oflead nephropa-
thy be traced and its relation to body lead
burden assessed. Also, it is only through
such studies that the predictive validity of
biomarkers ofearly renal impairment will
be confirmed.
MaleReproductiveToxicityofLead
Clinical and epidemiologic studies are
needed to assess the possible chronic toxic-
ity oflead to male fertility at lower levels of
exposure using state-of-the-art biologic
markers ofsperm function, such as assays
ofcervical mucus penetration and hamster
ovum penetration. These investigations
need to correlate results with lead body
burden as well as with ALAD phenotype.
Also, need exists to determine through
hormonal assays whether the male repro-
ductive toxicity oflead is mediated solely
by direct toxic effects on the testes, or
whether there are also toxic effects on
neuroendocrine function.
Studies are needed to assess the contri-
bution of chronic lead intoxication to
declining sperm counts. Perhaps to begin
this assessment, secular trends in sperm
count could be compared to trends in lead
exposure. Also international comparison
studies might be undertaken.
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NeurologicToxicity
Recent studies ofperipheral neurotoxicity
in asymptomatic adults exposed to lead
have used electrophysiologic probes to
determine whether lower level exposures
cause covert abnormalities in function.
With the development ofincreasingly sen-
sitive methodologies and the incorporation
of these methodologies into longitudinal
studies, it has become possible to detect
toxicity at progressively lower lead levels
(54). Thus, in a prospective study of
new entrants to the lead industry, slowing
of ulnar nerve conduction velocity was
reported at blood lead levels as low as 30 to
40 pg/dl (55).
In the central nervous system, the criti-
cal research question is whether lead causes
asymptomatic impairment in function at
doses insufficient to produce clinical
encephalopathy (10-14). While extensive
research into the subclinical neurobehav-
ioral toxicity oflead has been undertaken
in children (10-14), there is a striking lack
ofstudies ofchronic lead neurotoxicity in
adults (18). In one ofthe earliest available
investigations, a correlation was observed
between lead exposure and diminished
neuropsychologic performance in a group
ofasymptomatic workers, all ofwhom had
blood lead levels below 70 pg/dl (55). The
functions most severely impaired were
those dependent on visual intelligence and
visual-motor coordination. Also an
increased prevalence offatigue and short-
term memory loss was seen in smelter
workers exposed to lead; the prevalence of
these abnormalities increased with blood
lead levels (56).
Further clinical and epidemiologic
studies that use sophisticated markers
ofneurotoxicity in combination with mea-
sures oflead body burden and ALAD geno-
type will be required to establish the nature
and strength of the relationship in adults
between chronic exposure to lead and
decrements in central neurologic function.
Instruments that could be included
in such assessments will include both
computer-administered and manually
administered neuropsychological tests that
assess a range offunctional domains includ-
ing memory, cognition, psychomotor abili-
ties, attention, executive functioning, and
mood. Many ofthese functions are covered
by the Neurobehavioral Evaluation System
(NES) developed by Letz et al. (57).
Central neurologic function may also be
assessed through measurement ofsomato-
sensory evoked potentials, visual evoked
potentials, and brain stem auditory evoked
potentials. Peripheral neurologic function
can be assessed by a) nerve conduction
velocity assessment, including assessment
ofthe distribution ofconduction velocities;
b) hand strength dynanometry; and
c) quantitative grip testing. Of these
modalities, assessment ofnerve conduction
velocity is the traditional benchmark
(Araki et al., unpublished data).
Autonomic neurologic dysfunction in
persons chronically exposed to lead may be
assessed using neurophysiological assays
developed by Araki et al., such as assess-
ment of R-R interval variability (58).
Computerized assessment ofbalance and
postural sway, as pioneered by Battacharya
et al., provides an integrated measure of
the peripheral and central neurotoxicity of
lead (59).
Evaluation ofthe possible contribution
ofchronic lead intoxication to the etiology
of chronic neurodegenerative disease will
require case-control epidemiologic studies
ofpatients with such illnesses as Parkinson's
disease, dementia, and amyotrophic lateral
sclerosis. These studies will need to incor-
porate direct measurement ofbone lead by
XRF aswell as assessment ofALAD pheno-
type. The hypothesis that some fraction of
these diseases is caused by environmental
toxins, possibly including lead, needs to be
tested (60).
IsLeadMobilizedfrom Bone
aSource ofToxicity?
Lead can hypothetically be mobilized from
the skeleton under any circumstance that
increases bone mineral turnover. Potential
examples include pregnancy, lactation,
menopause, and hypermetabolic states
including Paget's disease ofbone and thy-
rotoxicosis (61,62). Mobilization oflead
from bone has been observed after retire-
ment among persons with many years of
occupational exposure to lead (63).
Assessment oflead mobilization in an
integrated marker-based research program
requires serial measurement ofbone lead
concentration by XRF coupled with mea-
surement ofbone densitometry; the mea-
surement of bone density provides an
indication oftotal bone mass. The product
ofmineral densityand bone lead concentra-
tion gives an index ofthe total amount of
lead in bone. Determination ofthis index
at various points in time in persons at risk
oflead mobilization could provide a quan-
titative index ofthe extent ofmobilization.
One population thought to be at
particularly high risk oflead mobilization
during pregnancy and lactation is young
women in inner-city areas of the United
States who may have had heavy exposure
to lead during their childhood. Typically,
the blood lead levels ofthese youngwomen
are normal when they reach reproductive
age. Concern exists, however, that some of
these women may have elevated concentra-
tions oflead in bone that place them at risk
of lead mobilization during pregnancy
and lactation.
Another population at potential risk of
lead mobilization during pregnancy and
lactation consists ofyoung women who
lived during childhood in the vicinity of
lead-emitting industrial facilities such as
smelters. Previous studies have docu-
mented high levels oflead exposure among
children living in such areas (64).
Lead mobilization during pregnancy is
potentially very hazardous to the fetus.
Lead passes across the placenta almost
without hindrance. Blood lead levels in
mother and fetus are usuallyidentical.
In women undergoing menopause,
concern exists that mobilization of lead
from bone during bone demineralization
may contribute to neuropsychological dys-
function (61). Assessment ofthis hypothe-
sis may be undertaken through serial
determination oflead in bone plus bone
densitometry coupled with assessment of
neuropsychological function in women
before, during and after menopause.
Conclusion
Chronic lead toxicity is a major health
problem in modern society, but is also a
potentiallypreventable problem.
Lead exposure and toxicity today reflect
the continuing use oflead in industry com-
bined with the legacy ofcareless use in the
past. Although lead consumption is less
today than previously, approximately
400,000 metric tonnes oflead are still used
each year in the United States (66) and
this lead appears in a wide array of con-
sumer products including batteries, solder,
pipes, ammunition, roofing, and X-ray
shielding (1). It may reliably be predicted
that lead exposure and lead toxicity will
continue to be problems for years to come.
The American epidemic oflead toxicity is
notyet over (67).
The integrated marker-based research
program proposed here offers a feasible
approach for understanding and control-
ling the current phase ofthe continuing
epidemic of chronic lead toxicity (65).
Information derived from a program such
as this will provide good data for good
public health decisions (68).
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We suggest that because of the wide
extent of the problem oflead exposure in
American society, support for research
into the chronic toxicity of lead should
continue to represent a major priority in
environmental public health. Even today
there is much that we do not know about
the toxicity of lead, and these gaps in
knowledge are impeding our ability to
control lead toxicity. We anticipate that
the results of research into the chronic
toxicity of lead will have substantial
benefits for public health in the United
States and the world, and that they will
make an important contribution to the
prevention ofchronic lead toxicity.
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